HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Xiaofang Wang Selected Research

Ovarian Neoplasms (Ovarian Cancer)

11/2020Retraction Note: Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis.
12/2018Long noncoding RNA DQ786243 interacts with miR-506 and promotes progression of ovarian cancer through targeting cAMP responsive element binding protein 1.
9/2018Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Xiaofang Wang Research Topics

Disease

45Neoplasms (Cancer)
05/2024 - 01/2003
19Inflammation (Inflammations)
11/2023 - 10/2008
19Infections
10/2023 - 06/2010
15Polycystic Kidney Diseases (Polycystic Kidney Disease)
05/2024 - 11/2003
14Autosomal Dominant Polycystic Kidney (ADPKD)
05/2024 - 11/2003
11Cysts
05/2024 - 11/2003
10Breast Neoplasms (Breast Cancer)
01/2024 - 06/2017
7Pre-Eclampsia (Preeclampsia)
02/2022 - 10/2015
7Neoplasm Metastasis (Metastasis)
01/2022 - 01/2003
6Multiple Myeloma
05/2024 - 01/2011
6Lung Neoplasms (Lung Cancer)
04/2024 - 01/2023
6Fibrosis (Cirrhosis)
11/2023 - 11/2003
6Pneumonia (Pneumonitis)
07/2022 - 01/2017
6Cardiomegaly (Heart Hypertrophy)
01/2022 - 01/2018
6COVID-19
11/2021 - 01/2020
6Hypertrophy
01/2021 - 01/2015
5Virus Diseases (Viral Diseases)
08/2023 - 01/2017
5Body Weight (Weight, Body)
04/2023 - 11/2003
5Malaria
01/2022 - 03/2011
5Huntington Disease (Huntington's Disease)
01/2019 - 06/2008
4Hypoxia (Hypoxemia)
12/2023 - 05/2010
4Heart Failure
08/2023 - 01/2022
4Myocardial Infarction
08/2023 - 12/2011
4Leukemia
01/2023 - 12/2019
4Cognitive Dysfunction
01/2023 - 06/2015
4Disease Progression
01/2021 - 01/2010
4Prostatic Neoplasms (Prostate Cancer)
01/2019 - 01/2014
4Autosomal Recessive Polycystic Kidney (Polycystic Kidney Disease, Infantile, Type I)
02/2009 - 03/2002
3Squamous Cell Carcinoma of Head and Neck
09/2023 - 01/2019
3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
08/2023 - 01/2018
3Wounds and Injuries (Trauma)
01/2023 - 11/2018
3Neurodegenerative Diseases (Neurodegenerative Disease)
01/2023 - 08/2009
3Type 2 Diabetes Mellitus (MODY)
12/2022 - 05/2018
3Triple Negative Breast Neoplasms
02/2022 - 06/2017
3Hepatocellular Carcinoma (Hepatoma)
01/2022 - 11/2018
3Bronchiolitis
01/2022 - 01/2020
3Pancreatic Neoplasms (Pancreatic Cancer)
01/2022 - 01/2015
3Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2022 - 10/2017
3Malnutrition (Nutritional Deficiencies)
09/2021 - 01/2017
3Human Influenza (Influenza)
01/2021 - 01/2019
3Coinfection
01/2021 - 11/2011
3Ovarian Neoplasms (Ovarian Cancer)
11/2020 - 09/2018
3Necrosis
11/2019 - 03/2015
3Pneumococcal Infections
01/2018 - 01/2017
2Carcinogenesis
01/2024 - 01/2015
2Adenocarcinoma of Lung
01/2024 - 11/2021
2Hypophosphatemia
12/2023 - 08/2014

Drug/Important Bio-Agent (IBA)

37Proteins (Proteins, Gene)FDA Link
09/2022 - 03/2002
17CytokinesIBA
11/2023 - 10/2008
14Biomarkers (Surrogate Marker)IBA
12/2023 - 09/2015
10Long Noncoding RNAIBA
11/2021 - 06/2017
9Antiviral Agents (Antivirals)IBA
08/2020 - 01/2017
8RNA (Ribonucleic Acid)IBA
01/2024 - 04/2019
8Therapeutic UsesIBA
11/2023 - 10/2008
8Glucose (Dextrose)FDA LinkGeneric
01/2023 - 03/2015
8EnzymesIBA
03/2019 - 01/2003
7Messenger RNA (mRNA)IBA
01/2023 - 01/2010
7Vasopressin Receptors (Arginine Vasopressin Receptor)IBA
10/2021 - 04/2005
7Vasopressins (Vasopressin)IBA
10/2021 - 01/2005
7CalciumIBA
10/2021 - 02/2009
6DNA (Deoxyribonucleic Acid)IBA
01/2024 - 03/2017
6Phosphotransferases (Kinase)IBA
01/2023 - 01/2016
6VaccinesIBA
11/2021 - 06/2010
6Angiotensin IIIBA
01/2021 - 10/2015
5MicroRNAs (MicroRNA)IBA
09/2023 - 01/2017
51,2,4-trioxaneIBA
01/2021 - 03/2011
4PoisonsIBA
04/2024 - 01/2023
4AntigensIBA
01/2024 - 02/2018
4Aspartate Aminotransferases (Aspartate Transaminase)IBA
01/2023 - 03/2015
4CateninsIBA
02/2022 - 08/2017
4pevonedistatIBA
03/2019 - 01/2014
32- (2,6- dimethylmorpholin- 4- yl)- N- (5- (6- morpholin- 4- yl- 4- oxo- 4H- pyran- 2- yl)- 9H- thioxanthen- 2- yl)acetamideIBA
04/2024 - 01/2023
3Type II DNA Topoisomerases (Topoisomerase II)IBA
04/2024 - 01/2023
3Oxygen (Dioxygen)IBA
11/2023 - 01/2019
3Hemoglobins (Hemoglobin)IBA
11/2023 - 05/2018
3AntioxidantsIBA
10/2023 - 01/2017
3LipidsIBA
08/2023 - 03/2015
3Streptozocin (Streptozotocin)FDA Link
01/2023 - 01/2019
3Alanine Transaminase (SGPT)IBA
01/2023 - 03/2015
3InterferonsIBA
10/2022 - 01/2020
3Immunoglobulin G (IgG)IBA
03/2022 - 06/2011
3Antimalarials (Antimalarial Agents)IBA
01/2022 - 11/2016
3artemisinin (artemisinine)IBA
01/2022 - 11/2016
3Competitive Endogenous RNAIBA
11/2021 - 01/2019
3Interleukin-6 (Interleukin 6)IBA
10/2020 - 01/2019
3Peptides (Polypeptides)IBA
02/2020 - 02/2018
3TolvaptanFDA Link
01/2020 - 04/2005
3Interferon Type IIBA
01/2020 - 01/2017
3Phosphoric Diester Hydrolases (Phosphodiesterases)IBA
01/2020 - 01/2016
3Ligases (Synthetase)IBA
03/2019 - 01/2014
3Small Interfering RNA (siRNA)IBA
03/2019 - 07/2015
3polyglutamineIBA
11/2017 - 08/2009
3AutoantibodiesIBA
01/2016 - 01/2013
2TRPP Cation ChannelsIBA
05/2024 - 01/2017
2Etoposide (VP 16)FDA LinkGeneric
01/2024 - 01/2023

Therapy/Procedure

33Therapeutics
01/2024 - 11/2004
9Radiotherapy
01/2023 - 06/2016
6Immunotherapy
01/2024 - 10/2021
5Mastectomy (Mammectomy)
01/2024 - 10/2017
2Intramuscular Injections
04/2024 - 01/2020